ES2292594T3 - E-selectina para tratar o prevenir accidentes cerebrovasculares. - Google Patents
E-selectina para tratar o prevenir accidentes cerebrovasculares. Download PDFInfo
- Publication number
- ES2292594T3 ES2292594T3 ES01939279T ES01939279T ES2292594T3 ES 2292594 T3 ES2292594 T3 ES 2292594T3 ES 01939279 T ES01939279 T ES 01939279T ES 01939279 T ES01939279 T ES 01939279T ES 2292594 T3 ES2292594 T3 ES 2292594T3
- Authority
- ES
- Spain
- Prior art keywords
- selectin
- administration
- tolerance
- administered
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000006011 Stroke Diseases 0.000 title claims description 45
- 108010024212 E-Selectin Proteins 0.000 claims abstract description 165
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 102000015689 E-Selectin Human genes 0.000 claims abstract 14
- 230000002787 reinforcement Effects 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 14
- 101000622123 Homo sapiens E-selectin Proteins 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 102000051210 human SELE Human genes 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 7
- 210000005013 brain tissue Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 102100023471 E-selectin Human genes 0.000 description 153
- 239000000427 antigen Substances 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 108091007433 antigens Proteins 0.000 description 34
- 238000000034 method Methods 0.000 description 26
- 239000000203 mixture Substances 0.000 description 22
- 241000700159 Rattus Species 0.000 description 21
- 108010058846 Ovalbumin Proteins 0.000 description 19
- 229940092253 ovalbumin Drugs 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 230000001629 suppression Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000000451 tissue damage Effects 0.000 description 11
- 231100000827 tissue damage Toxicity 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229940028885 interleukin-4 Drugs 0.000 description 9
- 208000010125 myocardial infarction Diseases 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229940076144 interleukin-10 Drugs 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- 108010036395 Endoglin Proteins 0.000 description 5
- 102100023472 P-selectin Human genes 0.000 description 5
- 102000003800 Selectins Human genes 0.000 description 5
- 108090000184 Selectins Proteins 0.000 description 5
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 5
- 230000006470 autoimmune attack Effects 0.000 description 5
- 230000000981 bystander Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000005951 type IV hypersensitivity Effects 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 102100037241 Endoglin Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 4
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012747 synergistic agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000000503 lectinlike effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108010046117 N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 102000033815 complement binding proteins Human genes 0.000 description 1
- 108091009760 complement binding proteins Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007798 limiting dilution analysis Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008249 pharmaceutical aerosol Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 231100000812 repeated exposure Toxicity 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009861 stroke prevention Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- XVQKZSLOGHBCET-INVHGPFASA-N tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine Chemical group CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC XVQKZSLOGHBCET-INVHGPFASA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20669300P | 2000-05-24 | 2000-05-24 | |
| US206693P | 2000-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2292594T3 true ES2292594T3 (es) | 2008-03-16 |
Family
ID=22767527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01939279T Expired - Lifetime ES2292594T3 (es) | 2000-05-24 | 2001-05-23 | E-selectina para tratar o prevenir accidentes cerebrovasculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7261896B2 (https=) |
| EP (2) | EP1286686B1 (https=) |
| JP (1) | JP4986361B2 (https=) |
| AT (1) | ATE367823T1 (https=) |
| AU (2) | AU6481301A (https=) |
| CA (1) | CA2410563C (https=) |
| DE (1) | DE60129552T2 (https=) |
| DK (1) | DK1286686T3 (https=) |
| ES (1) | ES2292594T3 (https=) |
| PT (1) | PT1286686E (https=) |
| WO (1) | WO2001089557A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7897575B2 (en) | 2000-05-24 | 2011-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
| WO2007028133A2 (en) * | 2005-08-30 | 2007-03-08 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
| WO2008045488A2 (en) * | 2006-10-09 | 2008-04-17 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Treatment of inflammation, demyelination and neuronal/axonal loss |
| US7261896B2 (en) * | 2000-05-24 | 2007-08-28 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Methods for preventing strokes by inducing tolerance to e-selectin |
| US20070244043A1 (en) * | 2005-03-10 | 2007-10-18 | Novavax, Inc. | Recombinant E-selectin made in insect cells |
| US7939078B2 (en) * | 2005-07-07 | 2011-05-10 | Codman & Shurtleff | Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue |
| WO2009038880A1 (en) * | 2007-08-01 | 2009-03-26 | Novavax, Inc. | Novel e-selectin variant |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3561444A (en) | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
| US3703173A (en) | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
| US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4635627A (en) | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
| US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
| US5399347A (en) | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
| US5081034A (en) * | 1988-11-14 | 1992-01-14 | Brigham & Women's Hospital | Cloned genes which encode elam-1 |
| DK0482089T3 (da) | 1989-07-14 | 1998-05-25 | Autoimmune Inc | Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker |
| CA2070281C (en) | 1989-12-20 | 2005-08-23 | David Allen Hafler | Improved treatment of autoimmune diseases by aerosol administration of auto antigens |
| AU651097B2 (en) | 1990-03-02 | 1994-07-14 | Autoimmune, Inc. | Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens |
| IL97709A (en) | 1990-03-30 | 2005-05-17 | Brigham & Womens Hospital | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| HUT69942A (en) | 1990-10-15 | 1995-09-28 | Brigham & Womens Hospital | Treatment of autoimmun diseases by oral administration of autoantigenes |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| IL99864A (en) | 1990-10-31 | 2000-11-21 | Autoimmune Inc | Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens |
| HU220357B (hu) * | 1992-02-28 | 2001-12-28 | Autoimmune Inc. | Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával |
| CA2133749A1 (en) | 1992-04-09 | 1993-10-28 | Howard L. Weiner | Suppression of t-cell proliferation using peptide fragments of myelin basic protein |
| AU5080393A (en) | 1992-08-17 | 1994-03-15 | Autoimmune, Inc. | Bystander suppression of retroviral-associated neurological disease |
| WO1995027499A1 (en) | 1994-04-08 | 1995-10-19 | Brigham And Women's Hospital | Treatment of autoimmune disease using oral tolerization and/or type i interferon |
| AU695883B2 (en) | 1994-04-08 | 1998-08-27 | Brigham And Women's Hospital | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines |
| US5891645A (en) * | 1994-06-01 | 1999-04-06 | Alexion Pharmaceuticals, Inc. | Porcine E-selectin |
| GB9507768D0 (en) * | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
| US5948407A (en) * | 1997-03-19 | 1999-09-07 | Shire Laboratories Inc. | Oral induction of tolerance to parenterally administered non-autologous polypeptides |
| US5935577A (en) | 1998-01-23 | 1999-08-10 | Autoimmune Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
| US20010056073A1 (en) * | 1998-07-21 | 2001-12-27 | Ascher Shmulewitz | Gene therapy method for revascularizing ischemic tissue |
| US6974573B2 (en) * | 1999-11-01 | 2005-12-13 | Mucovax Holdings, B.V. | Antibody production in farm animals |
| US7897575B2 (en) * | 2000-05-24 | 2011-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
| US7261896B2 (en) * | 2000-05-24 | 2007-08-28 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Methods for preventing strokes by inducing tolerance to e-selectin |
-
2001
- 2001-05-23 US US10/296,423 patent/US7261896B2/en not_active Expired - Fee Related
- 2001-05-23 EP EP01939279A patent/EP1286686B1/en not_active Expired - Lifetime
- 2001-05-23 JP JP2001585800A patent/JP4986361B2/ja not_active Expired - Fee Related
- 2001-05-23 EP EP10183986A patent/EP2295067A1/en not_active Withdrawn
- 2001-05-23 AT AT01939279T patent/ATE367823T1/de active
- 2001-05-23 DK DK01939279T patent/DK1286686T3/da active
- 2001-05-23 WO PCT/US2001/016583 patent/WO2001089557A2/en not_active Ceased
- 2001-05-23 AU AU6481301A patent/AU6481301A/xx active Pending
- 2001-05-23 CA CA2410563A patent/CA2410563C/en not_active Expired - Fee Related
- 2001-05-23 DE DE60129552T patent/DE60129552T2/de not_active Expired - Lifetime
- 2001-05-23 PT PT01939279T patent/PT1286686E/pt unknown
- 2001-05-23 AU AU2001264813A patent/AU2001264813B2/en not_active Ceased
- 2001-05-23 ES ES01939279T patent/ES2292594T3/es not_active Expired - Lifetime
-
2007
- 2007-06-19 US US11/820,326 patent/US20070253975A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1286686T3 (da) | 2007-11-19 |
| EP2295067A1 (en) | 2011-03-16 |
| DE60129552D1 (de) | 2007-09-06 |
| US7261896B2 (en) | 2007-08-28 |
| JP2004503471A (ja) | 2004-02-05 |
| CA2410563A1 (en) | 2001-11-29 |
| US20070253975A1 (en) | 2007-11-01 |
| CA2410563C (en) | 2013-04-23 |
| DE60129552T2 (de) | 2008-04-17 |
| ATE367823T1 (de) | 2007-08-15 |
| EP1286686B1 (en) | 2007-07-25 |
| EP1286686A2 (en) | 2003-03-05 |
| PT1286686E (pt) | 2007-11-07 |
| AU2001264813B2 (en) | 2005-12-08 |
| WO2001089557A2 (en) | 2001-11-29 |
| JP4986361B2 (ja) | 2012-07-25 |
| AU6481301A (en) | 2001-12-03 |
| US20040009125A1 (en) | 2004-01-15 |
| WO2001089557A3 (en) | 2002-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013040204A (ja) | コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療 | |
| US20210106652A1 (en) | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation | |
| ES2292594T3 (es) | E-selectina para tratar o prevenir accidentes cerebrovasculares. | |
| ES2433915T3 (es) | Vacunas de ADN que codifican proteínas de choque térmico | |
| AU2001264813A1 (en) | Methods for preventing strokes by inducing tolerance to E-selectin | |
| AU2005235514B2 (en) | Pharmaceutical formulations and methods for preventing or treating damage to brain tissue | |
| JP7242059B2 (ja) | シェーグレン症候群の治療用ペプチド | |
| EP1842551A1 (en) | E-selectin for treating or preventing stroke | |
| US20250064907A1 (en) | Therapeutic vaccines for treatment of chronic inflammatory diseases | |
| ES2778630T3 (es) | Composición multipeptídica | |
| JP2005529091A (ja) | エオタキシン伝達炎症状態の処置および予防方法および組成物 | |
| KR20060010730A (ko) | 염증 상태를 치료하고 예방하기 위한 방법과 조성물 | |
| EP3969463A1 (en) | Peptides and conjugates for treatment of arthritis | |
| JP2022537920A (ja) | 改良されたワクチン製剤 | |
| HK40012327A (en) | Peptides for treating sjogren's syndrome | |
| Newsom et al. | Sa. 39. Characterization and Clinical Response of a T-Cell Vaccination for Multiple Sclerosis |